Demo data. These are fictitious sample companies used to preview GroWiser. The figures are not real and are not investment information.
Chambal Biotech Ltd
NSE: CHAMBALBIOBSE: 549886Pharma Formulations
₹603.25
▲ 13.05 (+2.21%)
Profit & Loss
- FY22: 20,369
- FY23: 22,641
- FY24: 25,547
- FY25: 28,513
- FY26: 34,819
- FY22: 3,797
- FY23: 3,524
- FY24: 4,223
- FY25: 4,958
- FY26: 5,713
- FY22: ₹15.25
- FY23: ₹14.15
- FY24: ₹16.96
- FY25: ₹19.91
- FY26: ₹22.95
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue from operations | 20,369 | 22,641 | 25,547 | 28,513 | 34,819 |
| Operating expenses | 14,763 | 17,371 | 19,066 | 20,868 | 26,488 |
| Operating profit (EBITDA) | 5,606 | 5,270 | 6,481 | 7,645 | 8,331 |
| Other income | 323 | 241 | 215 | 241 | 487 |
| Depreciation | 574 | 627 | 772 | 910 | 805 |
| Interest | 293 | 185 | 293 | 366 | 396 |
| Profit before tax | 5,063 | 4,699 | 5,631 | 6,610 | 7,618 |
| Tax | 1,266 | 1,175 | 1,408 | 1,653 | 1,904 |
| Net profit | 3,797 | 3,524 | 4,223 | 4,958 | 5,713 |
| EPS (₹) | 15.25 | 14.15 | 16.96 | 19.91 | 22.95 |
| Dividend per share (₹) | 7.91 | 7.34 | 8.79 | 10.32 | 11.90 |
Figures in ₹ Cr unless marked per share (₹). Consolidated.
Showing 5 of 10 periods. Premium unlocks the full 10-year history. See Premium